The Finlay Institute of Vaccines, belonging to the Group of Biotechnological and Pharmaceutical Industries of Cuba, BioCubaFarma, signed a bilateral agreement with Iran to complement clinical evidence of the Sovereign 02 vaccine candidate.
A tweet from the largest company of the Antilles in the social network Twitter points out that this synergy will allow a faster progress in the immunization against Covid-19 in both countries.
BioCubaFarma in a message spread on the digital platform highlights that the Pasteur Institute of Iran has a long history of collaboration with institutions of the Group and today the friendship ties between the two nations are strengthened.
The Center of Molecular Immunology (CIM) commented that the complementation of scientific-technological capacities is vital to promote the accelerated development of effective therapies.
Cuba and its four vaccine candidates
In 2020, four vaccination candidates against Covid-19 were approved in Cuba, which are in several phases of clinical trials.
Last December 17, Soberana 02 passed to phase II of clinical trials, for which it constitutes the first Latin American drug to advance to that stage.
The vaccine candidate, in that phase, began to be applied in the last weeks of 2020 by means of vaccination, a process that passed with normality and with the strict fulfillment of the norms and sanitary protocols established for such cases.
Soberana 02 is a conjugated vaccine, in which the virus antigen, the receptor binding domain (RBD), is chemically linked to the tetanus toxoid. It is also innovative, as it has no precedent among all those developed, to face the new coronavirus in the world.
(Taken from ACN)